Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
NCT ID: NCT00031083
Last Updated: 2020-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
12 participants
INTERVENTIONAL
2002-04-02
2003-10-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Interferon-beta
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subjects must have histologically proven GBM, AA, AMO, malignant astrocytoma NOS or gliosarcoma and recurrent or progressive tumor following prior treatment.
3. Tumor must be amenable to radical resection, and resection must be clinically indicated.
4. Must have an ECOG performance status of 0-2.
5. Must be on anticonvulsant therapy, and must have therapeutic serum levels within 2 weeks prior to Day 1, if therapeutic levels are defined for the anticonvulsant being used.
Exclusion Criteria
* Alanine transaminase (ALT) \> four times (4X) the upper limit of normal (ULN).
* Aspartate transaminase (AST) \> 4X the ULN.
* Total bilirubin \>1.5 mg/dL.
* Absolute neutrophil count \<1,500 cells/mm3.
* Platelet count \<100,000 cells/mm3.
* Serum creatinine \>2X ULN.
* Prothrombin time (PT) \>2 seconds above the ULN.
* Serum sodium (Na) \<125 mEq/L or \>150 mEq/L.
* Serum potassium (K) \<3.5 mEq/L or \> 5.5 mEq/L.
2. Brainstem, or optic chiasm involvement of tumor.
3. Uncontrolled seizure disorder.
4. History of a new diagnosis or treatment of an invasive malignancy other than Grade III or Grade IV Glioma within 5 years of enrollment. Curatively treated subjects with a history of basal cell or squamous cell carcinoma of the skin, superficial transitional cell carcinoma of the bladder, and non-invasive carcinoma of the uterine cervix are not excluded.
Treatment History:
5. Treatment with radiation therapy, including interstitial radiation or radiosurgery, must be completed at least 8 weeks prior to Day 1.
6. Treatment with nitrosoureas must be completed at least 6 weeks prior to Day 1. Treatment with other chemotherapeutic agents must be completed at least 4 weeks prior to Day 1.
7. Treatment with any investigational drug or approved therapy for investigational use must be completed at least 4 weeks prior to Day 1.
8. History of intolerance to corticosteroids that would preclude use during this study, or history of any medical condition that precludes the use of corticosteroids.
9. Any prior treatment with a gene delivery vector, or an adenovirus therapeutic.
10. Women of child bearing potential must have a negative serum pregnancy test.
11. Women who are not postmenopausal, surgically sterile, or willing to practice effective contraception during the study. Men who are not surgically sterile or willing to practice effective contraception during the study.
12. Nursing mothers, pregnant women and women planning to become pregnant while on study.
13. Previous treatment with BG00001.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biogen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Biogen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
University of Arizona at Tucson
Tucson, Arizona, United States
University of Colorado Health Sciences Center
Denver, Colorado, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0101-453
Identifier Type: -
Identifier Source: secondary_id
C-1502
Identifier Type: -
Identifier Source: org_study_id
NCT00036725
Identifier Type: -
Identifier Source: nct_alias